The global food industry faces increasing scrutiny over pathogen control, particularly zoonotic bacteria like Campylobacter. Consumers and regulators demand safer food products and more humane, sustainable livestock practices. This technology aligns with these trends by providing a natural, targeted solution that enhances animal welfare while mitigating significant public health and economic risks for producers and processors worldwide.
Provides Campylobacter-specific bacteriostasis, selectively inhibiting key foodborne pathogens without affecting beneficial gut microbiota.
Utilizes a natural compound, tryptanthrin, ensuring high consumer acceptance and contributing to enhanced meat safety.
Secures long-term market exclusivity until 2041, offering a stable competitive advantage for business development.
This patent was granted after successfully demonstrating novelty and inventiveness against multiple prior art documents, ensuring a robust and stable right. It provides broad protection across 9 claims, covering both the bacteriostatic composition and its method of use, thereby minimizing future invalidation risks and securing legal stability for business operations.
While focused on Campylobacter, the underlying bacteriostatic mechanism could be explored for broader antimicrobial applications against other foodborne pathogens or in non-animal contexts, offering avenues for new IP development without conflict.
Economic losses from Campylobacter food poisoning, including recall costs, reputational damage, and liability risks, are estimated at $50K–$200K (AI est.) per incident. By introducing this technology and hypothetically reducing Campylobacter contamination rates by 5% at meat processing facilities, the annual number of incidents could be suppressed, potentially contributing to an annual loss avoidance of $0.5M–$2.0M (AI est.). The calculation is: (Annual incident reduction from contamination rate decrease) × (Average loss per incident).
X: Food Safety Contribution
Y: Cost-Effectiveness